tbuckley/cabot-search huggingface dataset:
Recurrent Collection of Drosophila melanogaster from Wild African Environments and Genomic Insights into Species History
Authors: Quentin D Sprengelmeyer, Suzan Mansourian, Jeremy D Lange, Daniel R Matute, Brandon S Cooper, Erling V Jirle, Marcus C Stensmyr, John E Pool
Journal: Molecular Biology and Evolution (2019)

Abstract A long-standing enigma concerns the geographic and ecological origins of the intensively studied vinegar fly, Drosophila melanogaster. This globally distributed human commensal is thought to originate from sub-Saharan Africa, yet until recently, it had never been reported from undisturbed wilderness environments that could reflect its precommensal niche. Here, we document the collection of 288 D. melanogaster individuals from multiple African wilderness areas in Zambia, Zimbabwe, and Namibia. The presence of D. melanogaster in these remote woodland environments is consistent with an ancestral range in southern-central Africa, as opposed to equatorial regions. After sequencing the genomes of 17 wilderness-collected flies collected from Kafue National Park in Zambia, we found reduced genetic diversity relative to town populations, elevated chromosomal inversion frequencies, and strong differences at specific genes including known insecticide targets. Combining these genomes with existing data, we probed the history of this species’ geographic expansion. Demographic estimates indicated that expansion from southern-central Africa began ∼13,000 years ago, with a Saharan crossing soon after, but expansion from the Middle East into Europe did not begin until roughly 1,800 years ago. This improved model of demographic history will provide an important resource for future evolutionary and genomic studies of this key model organism. Our findings add context to the history of D. melanogaster, while opening the door for future studies on the biological basis of adaptation to human environments.
Chlamydia pneumoniae and asthma
Authors: P J Cook, P Davies, W Tunnicliffe, J G Ayres, D Honeybourne, R Wise
Journal: Thorax (1998)

<h3>BACKGROUND</h3> This study was designed to test the association of <i>Chlamydia pneumoniae </i>infection with asthma in a multiracial population, after adjustments for several potential confounding variables. <h3>METHODS</h3> Antibodies to<i> C pneumoniae</i>were measured by microimmunofluorescence in 123 patients with acute asthma, 1518 control subjects admitted to the same hospital with various non-cardiovascular, non-pulmonary disorders, and 46 patients with severe chronic asthma, including some with "brittle" asthma. Acute infection or reinfection was defined by titres of IgG of ⩾512 or IgM ⩾8 or a fourfold rise in IgG, and previous infection by IgG 64–256 or IgA ⩾8. Logistic regression was used to control for likely confounders, including ethnic origin, age, sex, smoking habit, steroid medication, diabetes mellitus and social deprivation, on antibody levels. <h3>RESULTS</h3> Antibody titres consistent with acute<i>C pneumoniae </i>infection were found in 5.7% of patients with acute asthma and 5.7% of control patients, while 14.6% of patients with acute asthma and 12.7% of control patients had titres suggesting previous infection. These two groups did not differ significantly. However, titres suggesting previous infection were found in 34.8% of patients with severe chronic asthma: the difference between this group and the control group was statistically significant with an adjusted odds ratio of 3.99 (95% confidence interval 1.60 to 9.97). <h3>CONCLUSIONS</h3> These data raise important questions about the previously demonstrated association of <i>C pneumoniae</i> infection with asthma, and suggest that future studies of this association should give particular attention to the presence or absence of a history of severe chronic asthma.
Reflections on Mortality and Uncertainty in Emergency Medicine
Authors: Silas W. Smith, David C. Lee, Lewis R. Goldfrank
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
Authors: Guillermo Garcia-Manero, James McCloskey, Elizabeth A. Griffiths, Karen W.L. Yee, Amer M. Zeidan, Aref Al-Kali, Kim-Hien Dao, H. Joachim Deeg, Prapti A. Patel, Mitchell Sabloff, Mary-Margaret Keating, Nancy Zhu, Nashat Y. Gabrail, Salman Fazal, Joseph Maly, Olatoyosi Odenike, Aditi Shastri, Amy E. DeZern, Casey L. O'Connell, Gail J. Roboz, Aram Oganesian, Yong Hao, Harold N. Keer, Mohammad Azab, Michael R. Savona
Journal: Blood (2019)
Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort
Authors: Donald B. Kohn, Kit L. Shaw, Elizabeth Garabedian, Denise Ann Carbonaro-Sarracino, Theodore B. Moore, Satiro N. De Oliveira, Gay M. Crooks, John Tse, Sally Shupien, Dayna Terrazas, Alejandra Davila, Amalia Icreverzi, Allen Yu, Krista M. Chun, Christian E. Casas, Provaboti Barman, Maritess Coronel, Beatriz Campo Fernandez, Ruixue Zhang, Roger P. Hollis, Chilenwa Uzowuru, Hilory Ricketts, Jinhua Xu Bayford, Valentina Trevisan, Serena Arduini, Frances Lynn, Mahesh Kudari, Andrea Spezzi, Lilith Reeves, Kenneth Cornetta, Robert A. Sokolic, Roberta Parrott, Rebecca Buckley, Claire Booth, Fabio Candotti, Harry L. Malech, Adrian J. Thrasher, H. Bobby Gaspar
Journal: Blood (2019)
ACTR-46. TUMOR TREATING FIELDS COMBINED WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA: FINAL RESULTS FROM A PILOT STUDY
Authors: Rachel Grossman, Dror Limon, Felix Bokstein, Deborah Blumenthal, Camit Ben Harush, Zvi Ram
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Tumor Treating Fields (TTFields) are a non-invasive, loco-regional, anti-mitotic treatment comprising low intensity alternating electric fields approved for GBM. Preclinical data show that TTFields have a radio-sensitizing effect. This pilot study evaluated the safety and feasibility of TTFields/RT/TMZ in ndGBM patients. METHODS Patients with histologically confirmed ndGBM were treated with TTFields/RT/TMZ followed by maintenance TTFields and TMZ for up to 24 months. TTFields (200kHz) were delivered for &gt;18 hours/day with removal of the transducer arrays during RT delivery. TMZ was administered at 75 mg/m2/daily for 6 weeks and RT at a total dose of 60 Gy. The primary endpoint was safety of the combined TTFields/RT/TMZ; secondary endpoints included progression-free survival (PFS), overall survival (OS) and toxicity. Adverse events (AEs) were graded per CTCAE V4.0. RESULTS Ten patients were enrolled at a single center in Israel between April and December 2017. All patients had recovered from maximal debulking surgery or biopsy. Five patients (50%) had undergone gross total resection; rest had biopsy only. Median age was 59 and median KPS was 80. Median dose of RT was 60 Gy. Six patients (60%) reported at least one AE. The most common AE was TTFields-related skin toxicity reported in 4 patients (40%), of Grade 1–2 in severity. Two patients reported serious AEs (seizures and general deterioration) considered unrelated to TTFields. Median PFS with RT/TMZ/TTFields was 10.5 months. Median OS has not been reached. CONCLUSIONS The proportion of patients with TTFields-related skin toxicity was similar to that reported in EF-14 phase 3 study (52%). No other TTFields-related toxicities were reported. There was no increase in RT- or TMZ-related toxicities with TTFields/RT/TMZ combination. A phase 2 randomized study has been initiated to investigate the efficacy of concomitant RT/TMZ/TTFields in 60 ndGBM patients.
Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma
Authors: Akihiro Kitadate, Kentaro Narita, Kota Fukumoto, Toshiki Terao, Takafumi Tsushima, Hiroki Kobayashi, Yoshiaki Abe, Daisuke Miura, Masami Takeuchi, Youichi Machida, Naoto Takahashi, Kosei Matsue
Journal: Blood (2019)
Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera
Authors: Chi-Joan How, Orly Leiva, Thomas Bogue, Geoffrey Fell, Mark Bustoros, MD, Nathan T. Connell, Jean M. Connors, Irene M. Ghobrial, Nancy Higgins, Nicholas A Jessop, David J. Kuter, Jennifer Lombardi Story, Ann Mullally, Valentina Nardi, Donna S Neuberg, Rachel Styles, Jeffrey I. Zwicker, Gabriela S. Hobbs, Annemarie E Fogerty
Journal: Blood (2019)
Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study
Authors: Laurène Fenwarth, Raphael Itzykson, Stephane De Botton, Nicolas Duployez, Pierre Sujobert, Céline Berthon, Arnaud Pigneux, Sylvain Chantepie, Christian Recher, Emmanuel Raffoux, Juliette Lambert, Karine Celli-Lebras, Denis Caillot, Benoit Ducourneau, Pascal Turlure, Emilie Lemasle, Cecile Pautas, Norbert Vey, Sylvie Chevret, Christine Terré, Xavier Thomas, Claude Preudhomme, Herve Dombret
Journal: Blood (2019)
PATH-28. ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
Authors: Thomas Urup, Linn Gillberg, Katja Kaastrup, Maja Schuang Lü, Signe Regner Michaelsen, Vibeke A Larsen, Ib Jarle Christensen, Helle Broholm, Ulrik Lassen, Kirsten Grønbæk, Hans Skovgaard Poulsen
Journal: Neuro-Oncology (2019)

Abstract Recurrent glioblastoma patients achieving response to bevacizumab combination therapy have clinical improvement and prolonged survival. High gene-expression of angiotensinogen (AGT) is associated with a poor response to bevacizumab combination therapy. Because AGT gene-expression is epigenetically regulated, we investigate if lower AGT promoter methylation in tumor tissue predicts a poor response to bevacizumab combination therapy in recurrent glioblastoma patients. Methods: Patients were assessed for eligibility using our clinical database comprising all recurrent glioblastoma patients consecutively treated with bevacizumab combination therapy at our center. The study included 159 response and biomarker evaluable patients: A training cohort of 77 patients and a validation cohort of 82 patients treated in the period between year 2005–2011 and 2012–2015. DNA methylation of 4 CpG sites in the AGT promoter was measured using pyrosequencing. Using logistic regression analysis, a predictive model for non-response was established. Results: In the training cohort, lower methylation of each of the four CpG sites was significantly associated with non-response (p &lt; 0.05). Lower mean methylation of the AGT promoter was significantly associated with non-response (2-fold decrease: OR &amp;eq; 3.01; 95% CI:1.41–6.44; p &amp;eq; 0.004). A predictive model able to predict bevacizumab non-response in clinical practice was established. This predictor was significantly associated with non-response in the validation cohort (p &amp;eq; 0.037). Conclusion: AGT promoter methylation is lower in tumor tissue from non-responsive recurrent glioblastoma patients treated with bevacizumab combination therapy. A predictive model for non-response was established and successfully validated. This model can be used to identify patients who will not benefit from bevacizumab combination therapy.
A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)
Authors: Fuad A El Rassi, Deepika S. Darbari, Arthur Burnett, Jincy Paulose, Dramane I Laine, Das Purkayastha, Gregory J Kato
Journal: Blood (2019)
The Waning Power of Penicillin
Authors: G. G. Thyne
Journal: BMJ (1947)

From a limited experience of the operation the impression is gaining ground that the presence of pre-morbid obsessional traits is of good prognostic significance when considering candidates for leucotomy.This appears not only to explain the good results claimed in obsessional neurosis and depression but appears to be at the.back of the improvement obtained in this case.Before accepting the operation as the treatment of choice in any case of psychoneurosis a thorough exploration and evaluation of the psychodynamic factors are indicated, and only if these are considered unmodifiable by any other practicable means should the operation be recommended.-I am, etc.,
Coronary Microvascular Dysfunction Causing Cardiac Ischemia in Women
Authors: Janet Wei, Susan Cheng, C. Noel Bairey Merz
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RARE-09. CYSTIC GLIOBLASTOMA PRESENTATION AS A BENEFICIAL PROGNOSTIC INDICATOR FOR OVERALL SURVIVAL
Authors: Lee Curtin, Paula Whitmire, Cassandra Rickertsen, Peter D Canoll, Maciej Mrugala, Kristin Swanson, Leland Hu
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most aggressive primary brain tumor with a median overall survival of 15 months with standard-of-care treatment. GBM patients sometimes present with a cystic component, which can be identified through magnetic resonance imaging (MRI). Previous studies suggest that cysts occur in 7–22% of GBM patients and have reported mixed results regarding whether cystic GBM have a survival benefit compared to noncystic GBM. Using our large retrospective cohort of 493 first-diagnosis GBM patients, we aim to elucidate this link between cystic GBM and survival. Within this cohort, 88 patients had a significant cystic component at presentation as identified on MRI. Compared to noncystic GBM (n=405), cystic GBM patients had significantly better overall survival (15 vs 22 months median, log-rank, p=0.001) and were significantly younger at the time of presentation (t-test, p=0.002). However, within patients that received current standard-of-care treatment (n=184), cystic GBM (n=40) was not as beneficial for outcome (22 vs 25 months, log-rank, p=0.3). We also did not observe a significant survival benefit when comparing this standard-of-care cystic cohort to cystic GBM patients diagnosed before the standard was established (n=19, 25 vs 23 months, log-rank, p=0.3), but the analogous result for noncystic GBM patients gives a sizeable benefit, as expected (n=144, n=111, respectively, 22 vs 12 months, log-rank p &lt; 0.0001). Together, these results on current standard-of-care may explain later studies that note no significant survival benefit for cystic GBM patients receiving current standard-of-care. We also report differences in the absolute and relative sizes of imaging abnormalities on MRI and in prognostic impact of cysts based on sex. We discuss current hypotheses for these observed differences, including the possibility that the presence of a cyst could be indicative of a less aggressive tumor.
NIMG-34. MULTI-PARAMETRIC MR-PET IMAGING PREDICTS PHARMACOKINETICS AND CLINICAL RESPONSE TO GDC-0084 IN HUMAN RECURRENT HIGH-GRADE GLIOMA
Authors: Benjamin Ellingson, Jingwen Yao, Catalina Raymond, David Nathanson, Jeremy Simpson, James Garner, Alan Olivero, Lars Mueller, Jordi Rodon, Elizabeth Gerstner, Timothy Cloughesy, Patrick Wen
Journal: Neuro-Oncology (2019)

Abstract Alterations in the PI3K pathway are found in the majority of malignant gliomas, but lack of efficacy has caused investigators to question the viability of this target, particularly due to lack of brain penetration. GDC-0084 was specifically optimized to penetrate the brain, targeting both PI3K and mTOR. Since these two targets alter tumor vascularity and metabolism, respectively, we hypothesized that multi-parametric MR-PET could be used to quantify the response, estimate pharmacokinetic (PK) parameters, and predict progression-free survival (PFS) in patients with recurrent malignant gliomas. In this first-in-man, multicenter, phase I, dose-escalation study (NCT01547546), we show in 47 patients that the measured maximum concentration (Cmax) of GDC0084 was associated with a decrease in enhancing tumor volume (P=0.0287) and an increase in fractional anisotropy (FA) (P=0.0418). Post-treatment tumor volume, 18F-FDG uptake, Ktrans, and relative cerebral blood volume (rCBV) were all correlated with Cmax. A linear combination of change in 18F-FDG PET uptake, apparent diffusion coefficient (ADC), FA, Ktrans, vp, and rCBV were able to estimate both Cmax (R2=0.4113, P&lt; 0.0001) and drug exposure (AUC) (R2=0.3481, P&lt; 0.0001). Using this composite multi-parametric MR-PET imaging response biomarker to predict PK, patients with an estimated Cmax &gt;0.1 uM and AUC &gt; 1.25 uM*hr demonstrated significantly longer PFS compared with patients with a lower estimated concentration and exposure (P=0.0039 and P=0.0296, respectively). Results from the current study suggest composite biomarkers created from multi-parametric MR-PET imaging targeting metabolic and/or physiologic processes specific to the drug mechanism of action may be useful for subsequent evaluation of treatment efficacy for larger phase II-III studies.
Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia
Authors: Maher Albitar, Marina Y Konopleva, Hong Zhang, Ivan De Dios, Wanlong Ma, Spiraggelos Antzoulatos, Steven M. Kornblau, Antonio Cavazos, Sanam Loghavi, Koichi Takahashi, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood (2019)
Rationale for Targeting BCL6 in MLL-Rearranged B-ALL
Authors: Lai N Chan, Christian Hurtz, Huimin Geng, Erica Ballabio, Gang Xiao, Gauri Deb, Haytham Khoury, Scott A. Armstrong, Patricia Ernst, Ari Melnick, Tom Arthur Milne, Markus Müschen
Journal: Blood (2019)
SCIDOT-30. GLITIPNI: A PHASE 1B CLINICAL TRIAL COMBINING SURGICAL RESECTION WITH DIRECT INTRACEREBRAL INJECTION OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Authors: Johnny Duerinck, Gil Awada, Julia Katharina Schwarze, Ines Dufait, Stephanie Peeters, Laura Seynaeve, Anne-Marie Van Binst, Hendrik Everaert, Alex Michotte, Anne Rogiers, Vera Van Velthoven, Bart Neyns
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Intravenous (iv) administration of PD-1 blocking mAb is largely ineffective for the treatment of recurrent glioblastoma (rGB). Combination of iv-ipilimumab (IPI) plus nivolumab (NIVO) is associated with a high incidence of irAE. Intracerebral (ic) administration of immune-checkpoint inhibiting mAb following the resection of rGB could be a more effective and safer alternative to iv-dosing. METHODS Patients underwent maximal safe resection of their rGB followed by ic-injection of 10mg IPI (cohort-1) or 5mg IPI plus 10mg NIVO (cohort-2) in the wall of the resection cavity. In both cohorts 10mg nivolumab was administered iv for a max of 6 doses, starting 1 day pre-operatively. RESULTS 21 pts were included (3 in C-1, 18 in C-2; 8F/13M; median age 56y [range 38–72]; 17 de novo GB, 4 secGB). All patients underwent maximal safe surgical resection followed by ic-injection of IPI and NIVO as planned. Median number of iv-administrations of NIVO was 5 (range 1–8). Treatment was generally well tolerated. Postoperatively, 2 patients experienced a G3 symptomatic increase in perilesional cerebral edema with neurological deterioration, reversible upon steroid treatment. One patient had worsening neurological symptoms related to an inflammatory intracerebral cyst at the resection site, requiring surgical decompression 4 months post-study treatment. Most frequent AEs were fatigue (2pts G3, 8pts G2), postoperative fever (11pts G1) and headache (3pts G2); 1pt developed G3 pneumonitis. No other immune-related AEs or treatment-related deaths occurred. After median follow-up of 60 weeks, median PFS is 14.4 weeks (95% CI 11.2–17.6); 11/21 patients are alive, and 1- and 2y-OS% are respectively 46% (95% CI 19- 73%), and15% (95% CI 0–42%). CONCLUSION This is the first study demonstrating the safety and activity of combined surgical resection of rGB with local intracerebral administration of immune checkpoint-inhibiting mAb. Survival compares favorably to historical controls justifying further investigation of this experimental therapy.
Patients with Familial Thrombophilia of Unknown Origin Show Low APC Response to In Vivo Thrombin Formation in Stimulated Hemostasis Activity Pattern Evaluation (SHAPE)
Authors: Heiko Rühl, Sara Reda, Franziska Isabelle Winterhagen, Christina Berens, Jens Müller, Johannes Oldenburg, Bernd Pötzsch
Journal: Blood (2019)
CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
Authors: Ekaterina Kim, Hongying Zhang, Mariela Sivina, Alicia Vaca, Philip A. Thompson, Nitin Jain, Alessandra Ferrajoli, Zeev E. Estrov, Michael J Keating, William G. Wierda, William G Rice, Michael Andreeff, Jan A. Burger
Journal: Blood (2019)
Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach
Authors: Phoebe Tsz Man Cheng, Diego Villa, R. Petter Tonseth, David W. Scott, Alina S Gerrie, Ciara L Freeman, Christina Aquino Parsons, Tom Pickles, Andrea Lo, Don Wilson, Brian Skinnider, Laurie H Sehn, Joseph M Connors, Kerry J Savage
Journal: Blood (2019)